Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
FREMONT, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023.
Related news for (CTKB)
- Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/04/25 05:00 PM
- MoBot’s Stock Market Highlights – 06/04/25 04:00 PM
- MoBot alert highlights: NASDAQ: CTKB, NASDAQ: LYEL, NYSE: NCL, NYSE: BURU, NASDAQ: MFI (06/04/25 03:00 PM)
- Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference